Aktuelle Forschungsprojekte der ÖPG

ÖPAR (österreichisches Parkinson Register)

Morbus Parkinson ist eine neurodegenerative Erkrankung, die durch die klassischen motorischen Zeichen Tremor (Zittern), Rigor (Muskelsteifigkeit) und Bradykinese (Bewegungsverlangsamung) gekennzeichnet ist. Neben diesen Kardinalsymptomen bietet die Parkinsonerkrankung jedoch ein breites Spektrum weiterer Symptome, die im Verlauf der Erkrankung auftreten können. Dazu zählen, neben den bereits genannten motorischen Merkmalen, auch zahlreiche nicht-motorische Symptome wie zum Beispiel: Abnahme der Gedächtnisleistung, Störungen des Schlafes, der Blasen- und oder Mastdarmfunktion, sowie depressive Symptome und Schmerzen. In fortgeschrittenen Krankheitsstadien kommt es darüber hinaus häufig zur Entwicklung motorischer Langzeitkomplikationen wie Wirkfluktuationen und Dyskinesien (zuckende oder drehende unwillkürliche Bewegungen).

Um das Ausmaß und die Schwere dieser breiten Palette an Symptomen in der klinischen Praxis zu erfassen, werden bestimmte neurologische Untersuchungen durchgeführt. Die Erfassung dieser gewonnenen Daten dient dem Arzt zur Beurteilung des aktuellen Gesundheitszustandes des Patienten.

Die österreichische Parkinsongesellschaft möchte mit diesem Register eine österreichweite Datenbank von Patienten mit Morbus Parkinson erstellen. Dieses soll den Zweck erfüllen Meilensteine der Erkrankung und sozioökonomische Aspekte besser zu definieren. Des Weiteren kann diese Datenbank auch zur Rekrutierung von Studien verwendet werden.

TOP-Publikationen der ÖPG

Beginn nicht-motorischer Symptome bei Morbus Parkinson

The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).

AutorInnen: Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, Mas N, Hofeneder D, Brücke T, Bayés A, Wenzel K, Infante J, Zach H, Pirker W, Posada IJ, Álvarez R, Ispierto L, De Fàbregues O, Callén A, Palasí A, Aguilar M, Martí MJ, Valldeoriola F, Salamero M, Poewe W, Tolosa E.

Journal: Mov Disord. 2015 Feb;30(2):229-37. doi: 10.1002/mds.26077. Epub 2014 Dec 1.

Abstract: Several randomized placebo-controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo-controlled parallel-group study was performed to assess the long-term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year- were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1-4.03) at baseline to 4.28 (95% CI, 3.1-5.4) at three-week follow-up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1-4.4) to follow-up 3.6 (95% CI, 2.3-4.8) in patients staying on amantadine. These findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.

 

Amantadin: Langzeitwirksamkeit gegen Dyskinesien bei Morbus Parkinson

Long-term antidyskinetic efficacy of amantadine in Parkinson's disease.

AutorInnen: Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W.

Journal: Mov Disord. 2010 Jul 30;25(10):1357-63. doi: 10.1002/mds.23034.

Abstract: Several randomized placebo-controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo-controlled parallel-group study was performed to assess the long-term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year- were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1-4.03) at baseline to 4.28 (95% CI, 3.1-5.4) at three-week follow-up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1-4.4) to follow-up 3.6 (95% CI, 2.3-4.8) in patients staying on amantadine. These findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.